PDGFR and KDR Inhibitors for Liver Fibrosis

? DESCRIPTION (provided by applicant): The incidence and prevalence of both alcoholic and non-alcoholic liver diseases is increasing. The population presenting with Metabolic Syndrome, a key risk factor for NAFLD-NASH-liver fibrosis is ballooning. Leftuntreated, liver fibrosis can progress to cirrhosis or end-stage liver disease and even hepatocellular carcinoma. Today, therapeutic strategies are primarily geared toward mitigating NAFLD-NASH via diet modification, exercise and medication. Unfortunately, there is no approved therapy for established liver fibrosis other than organ transplantation. The proposed translational research program is designed to bring to clinical trials an outstanding and highly promising orally bioavailable small molecule antifibrotic to clinical trials for the treatment of liver fibrosis. Anion Biomedica has identified ANG3070, a potent, highly water-soluble, orally bioavailable, small molecule platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth fact